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Abstract
We report a scalable and cost-effective technology for generating and screening high-complexity customizable peptide
sets. The peptides are made as peptide-cDNA fusions by in vitro transcription/translation from pools of DNA templates
generated by microarray-based synthesis. This approach enables large custom sets of peptides to be designed in silico,
manufactured cost-effectively in parallel, and assayed efficiently in a multiplexed fashion. The utility of our peptide-cDNA
fusion pools was demonstrated in two activity-based assays designed to discover protease and kinase substrates. In the
protease assay, cleaved peptide substrates were separated from uncleaved and identified by digital sequencing of their
cognate cDNAs. We screened the 3,011 amino acid HCV proteome for susceptibility to cleavage by the HCV NS3/4A
protease and identified all 3 known trans cleavage sites with high specificity. In the kinase assay, peptide substrates
phosphorylated by tyrosine kinases were captured and identified by sequencing of their cDNAs. We screened a pool of
3,243 peptides against Abl kinase and showed that phosphorylation events detected were specific and consistent with the
known substrate preferences of Abl kinase. Our approach is scalable and adaptable to other protein-based assays.
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Introduction
The pace of improvement in DNA sequencing technologies is
far outpacing Moore’s Law [1]. As a result, many new whole
genome sequences are rapidly becoming available for analysis.
This has created a pressing need for new technologies that enable
the translation of genomic sequence information into information
about protein function at the level of the proteome. Here we
address this need by reporting a new approach for producing and
assaying large, customizable sets of peptide-cDNA conjugates that
combines efficient enzymatic synthesis of in silico designed peptide
sequences with intrinsically parallel assay formats designed for
readout by DNA sequencing.
A variety of molecular biology techniques for the production
and screening of large numbers of proteins or peptides linked to
their encoding nucleic acid sequences has been developed,
primarily to enable the discovery of high affinity binders to targets
of interest. These methods, which include phage display [2–7],
PROfusion
TM technology [8,9], and others [10–18], provide
means to identify enriched proteins via a nucleic acid tag and
avoid the limitations of chemical synthesis (e.g. racemization,
limited peptide length, complex multistep synthesis, and use of
toxic chemicals) [19].
The sequence diversity of such biologically and biochemically
produced constructs is typically generated combinatorially by
randomization of nucleic acid sequences [20–23]. Although
combinatorial approaches are very efficient and straightforward
to implement, they are not suitable for representing custom sets of
protein sequences of interest, such as the human proteome and its
common variations, in a compact form. For example, a random
combinatorial library of 10-mer peptides would comprise 20
‘10, or
approximately 10
‘13, sequences. This is larger than the coding
content of the ,3610
‘9 base pair human genome by several
orders of magnitude. We address this limitation by making use of
microarray-based design and synthesis of custom DNA oligonu-
cleotide sequences to encode specific peptide sequences of interest.
The peptide libraries made in this way are smaller than typical
random combinatorial libraries, but orders of magnitude larger
than conventional custom libraries. Importantly, they can be
designed to represent collections of biologically relevant sequences
of high interest and utility, such as the human proteome.
Our approach to utilizing peptide-cDNA conjugates also differs
from traditional selection-based assays, which use multiple rounds
of selection to enrich for a small number of ‘hits’ with desired
properties, typically those that bind with the highest affinity
[2,12,21,24]. Instead, we seek to obtain information from large
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6numbers of peptides simultaneously in one experiment, generating
comprehensive datasets that provide more systematic insight by
reporting on a broad spectrum of interactions. In order to illustrate
this approach, we designed and developed two types of
multiplexed activity assays that employ large custom collections
of peptide-cDNA conjugates; one for proteases and one for
kinases. Both classes of enzymes have been implicated in a
multitude of critical physiological and pathological processes.
Therefore, novel multiplexed assays with the capacity to analyze
the activity of these enzymes on a proteome-wide scale may find
broad application.
Proteases and kinases are involved in two essential regulatory
processes, proteolysis and phosphorylation. Proteases activate or
terminate biological signaling events through the destruction of
proteins [25–27]. Similarly, kinases activate or deactivate enzymes,
and enable cell signaling, through reversible phosphorylation
[28,29]. Both enzyme classes are involved, often together, in
regulation of crucial cellular processes such as DNA replication,
cell cycle progression, differentiation, and apoptosis. Misregulation
of proteolytic or/and phosphorylation activity is therefore involved
in many pathologies including cancer, autoimmune diseases,
degenerative diseases, cardiovascular diseases and infectious
diseases [30–34]. The discovery of potential protease and kinase
targets genome-wide may help to elucidate their role in the cell,
guide structure and function studies of these enzymes, identify
novel drug targets within an important class of ‘druggable’
proteins, and enable the development of new diagnostic tools
[28,29,31,35–43].
In addition to protease and kinase substrate screening, the
approach presented in this report can be used in the selection of
peptide substrates for other classes of protein modifying enzymes
[44,45], epitope mapping [46,47], engineering of new classes of
enzymes [48], development of new materials in biotechnology and
biomedicine [49], discovery of peptide ligands for proteins [50],
semiconductor surfaces [51,52], specific cell types including cancer
cells [4], and identifying agents for efficient and specific delivery of
imaging labels [53].
Results
Generation of cDNA-peptide Fusions and
Assay Optimization
Our processes for making and assaying peptide-cDNA pools are
illustrated in Fig. 1. The production process that we used is similar
to one described earlier for combinatorial peptide libraries [8].
DNA oligonucleotides obtained by microarray-based synthesis
were converted into dsDNA templates encoding peptide sequenc-
es. The library was then transcribed to produce mRNAs, and a
DNA adapter conjugated to puromycin was ligated to the 3’ end of
the mRNAs. During subsequent in vitro translation of mRNAs,
puromycin entered the ribosome A-site and attached to the C-
terminus of the nascent peptide, forming a covalent fusion between
the peptide and its encoding mRNA. Peptides were then cleaved at
a specific location by TEV protease to generate an N-terminal
cysteine, which was biotinylated to allow capture and purification
of the fusion molecules. The mRNA portion of the fusion was then
converted into cDNA by reverse transcription and RNAse H
treatment. Alternatively, conversion to cDNA can be done after in
vitro translation and prior to TEV protease cleavage.
We first established all the steps of peptide-cDNA fusion
formation using individually synthesized DNA templates (Fig. 2A–
B). A critical step of the process is peptide-RNA fusion formation
during in vitro translation. The conversion efficiency of RNA-
puromycin molecules to RNA-peptide fusions was studied and
estimated by gel-electrophoresis to be about 50% (Fig. 2A).
Cleavage of the peptide-RNA fusion by TEV protease and
subsequent biotinylation was monitored in a similar way (Fig. 2B).
In order to confirm that full-length peptides were synthesized, the
RNA-peptide molecules were captured on magnetic beads and the
C-terminal tag detected (Fig. 2C). In a single-substrate protease
assay (Fig. 1, step (v)), peptide-RNA fusions coding for enteroki-
nase and thrombin substrates were captured separately on
streptavidin coated beads and subjected to cleavage with
individual proteases. Cleavage was confirmed by a change in gel
electrophoretic mobility (Fig. 2D) and RNA quantification
Figure 1. Process for protease and kinase peptide substrate
generation and screening. i) DNA templates containing a T7
promoter (1), ribosomal binding site (2) [100–103], sequences coding
for N- and C-terminal peptide tags (3, 5), a variable region (4) coding
for custom peptide sequences, and an adapter ligation region (6) are
transcribed and a DNA adapter is attached to the 3’-end of all RNAs via
template-directed ligation [8]. The adapter consists of DNAs (7) and
(11) cross-linked via a psoralen residue (8), a linker (9), and a 3’-
puromycin residue (10). ii–iii) During in vitro translation, a stalled
ribosome (12) allows the puromycin residue to enter the ribosome A-
site and attach to the C-terminus of the peptide, creating an peptide-
RNA fusion [9]. Each peptide in the fusion pool has a custom peptide
region (14) and two tags (13) and (15). The C-terminal tag can be used
to purify correctly translated full-length peptides. iv) The N-terminal
peptide sequence is cleaved with TEV protease to expose N-terminal
cysteine which is then biotinylated (16). The RNA is converted to cDNA
by reverse transcription followed by RNAse H treatment [8], and the
resulting peptide-cDNA fusions are immobilized on streptavidin coated
magnetic beads (17). v) Protease Assay. In a subsequent assay
procedure, the immobilized pool is treated with a protease of interest.
The cDNAs attached to cleaved peptides (18) are released, collected,
amplified, and sequenced. vi) Kinase Assay. The pool of peptide-cDNA
fusions is released from streptavidin coated magnetic beads (17) and
treated with a solution containing tyrosine kinase. Phosphorylated
peptides (19) are immobilized on anti-phosphorotyrosine antibody
coated magnetic beads (20), specifically eluted with phenyl phosphate,
collected, amplified, and sequenced.
doi:10.1371/journal.pone.0037441.g001
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(vi)), a single cDNA-peptide fusion containing Abl substrate
(GEAIYAAPFA) was treated with Abl kinase. Phosphorylated
cDNA-peptide fusion was then captured on magnetic beads coated
with anti-phosphotyrosine antibodies [40,54] and subsequently
eluted and quantitated by qPCR. We detected over 128-fold
enrichment of the phosphorylated peptide over non-phosphory-
lated negative control.
Multiplexed Protease Assay
In order to validate the peptide-cDNA conjugate pools in a
multiplexed functional assay, and demonstrate the scalability of
our technology, we studied the substrate specificity of NS3/4A
(hepacivirin) protease of hepatitis C virus (HCV), a major cause of
morbidity and mortality worldwide [55]. The viral genome is
translated into a single polyprotein of 3,011 amino acids that is
cleaved at four sites by the HCV NS3/4A protease [56]. This
protease is essential for viral replication and the formation of
infectious viral particles, and thus has been considered an
attractive target for HCV therapy [57–61]. Nevertheless, there is
relatively little data available regarding the substrate specificity of
the HCV NS3/4A protease. Only the four biologically relevant
peptide substrates have been reported [62] and listed in the
MEROPS protease database as 8-mer peptides [26]: NS3/4A-
NS4A (
1654EVVTQSTWV
1661), NS4A-NS4B
(
1708MEECQSQHL
1715), NS4B-NS5A (
1969TTPCQSGSW
1976)
and NS5A-NS5B (
2417VVCCQSMSY
2424).
We produced a set of 3,001 DNA templates coding for 10-mer
overlapping peptide sequences derived from the HCV polyprotein
with a step of one amino acid. Next, we converted these templates
into corresponding peptide-cDNA conjugates and confirmed that
all the expected conjugates were present, by sequencing following
purification via N-terminal biotin capture (see Methods for details).
The pool of cDNA-peptide fusions was immobilized on magnetic
beads and used to assay protease activity (see Methods). The HCV
NS3/4A protease cleavage data for the 3,001-plex peptide set are
presented in Fig. 3. Although the overall background was low, the
presence of a few sporadic peaks indicated that there is some
random noise in this assay. Therefore, we used a more stringent
criterion of requiring that a signal be present at all three time
points in order to be considered a clear positive. By this criterion,
we detected cleavage of the three known trans sites published in the
MEROPS database (
1708MEECQSQHL
1715,
1969TTPCQSGSW
1976, and
2417VVCCQSMSY
2424, labeled
1711, 1972, and 2420 respectively in Fig. 3). The fourth NS3/
4A-NS4A site (
1654EVVTQSTWV
1661) was not detected in our
assay. This site is cleaved in cis, i.e. via an intramolecular cleavage
event, and therefore would not be expected to be detected [63,64].
We also identified a cleavage site (
2168VAVLTQSMLTD
2177 )
that was not reported previously (labeled as 2172 in Fig. 3). Results
from individual peptides that span the four cleavage sites are
shown in Fig. 4. In order to verify our results, and to evaluate the
significance of the sporadically detected sites (labeled in red in
Fig. 3), individual peptides were chemically made, treated with
HCV NS3/4A protease, and analyzed by HPLC and LCMS (See
Figure 2. Individual steps of the peptide substrate generation and screening process. A) Peptides were attached to RNA as shown in Fig.
1, steps (ii–iii) and reaction products analyzed by denaturing polyacrylamide gel electrophoresis (PAGE, Novex 15% TBE-Urea gels stained with SYBR
Gold, Life Technologies). PAGE Lane 1: starting RNA with puromycin adapter; Lane 2: product of peptide attachment. B) Peptides were biotinylated at
their N-terminus as shown in Fig. 1, step (iv). PAGE Lane 1: starting nucleic acid-peptide fusion; Lane 2: product of cleavage with TEV protease; Lane 3:
product of reaction of biotin-PEG attachment to the N-terminal cysteine. C) Presence of fully translated peptide (3–4–5) was confirmed by detection
of the C-terminal FLAG tag (5) by mouse anti-FLAG antibodies (Sigma) (1) and Cy3 labeled goat anti-mouse antibodies (Jackson ImmunoResearch)
(2). Peptide-RNA fusions were captured by hybridization of a common region (6) to oligonucleotides (7) attached to beads (8). Beads were imaged
using a DM6000B automated fluorescence microscope and imaging system (Leica). Bar 1 represents in vitro translation in the presence of puromycin
modified template; Bar 2 is a no template control; Bar 3 is puromycin modified template without in vitro translation. D) Protease assay results. The
process is shown in Fig. 1, step (v). Individual peptide-RNA fusions containing peptide substrates for enterokinase (EK) and thrombin (TRB) proteases
(AGDDDDKAG and GLVPRGSAG respectively) were cleaved by individual proteases and the reaction products were analyzed by PAGE. Lanes 1–3
show results for peptide substrate for enterokinase (EK), lanes 4–6 show results for peptide substrate for thrombin (TRB). E) Quantitative RT-PCR
analysis of the assays shown in panel D, lanes 2–3 and 5–6. The Y-axis represents relative DNA quantities calculated from qPCR Ct values.
doi:10.1371/journal.pone.0037441.g002
Scalable Peptide-Based Assay System for Proteomics
PLoS ONE | www.plosone.org 3 June  2012 | Volume 7 | Issue 6 | e37441Text S1 and Table S1 for details). All four positives were
confirmed, and one of two sporadic positives tested was detected as
cleaved. However, only the three known positives were detected by
HPLC, which is less sensitive than LCMS, indicating that the
newly detected sites are cleaved less efficiently. A more detailed
analysis of NS3/4A specificity was carried out using a collection of
8-mer peptides and is reported in an accompanying paper [65].
Multiplexed Protein Kinase Assay
The ability to discover potential protein kinase substrates and
assay them at high resolution across the proteome would help
guide experiments to elucidate the functional roles of specific
kinases [37–43]. In order to demonstrate the feasibility of such an
approach, we designed and synthesized a 3,243-plex set of 10-mer
peptides for kinase assays. The identity of peptide-cDNA
conjugates was confirmed by sequencing as described for the
protease assay above. The pool included kinase peptide substrates
and negative controls published earlier [66–70], and kinase
peptide substrates obtained from phosphoroproteomics databases
[70–73]. Additionally, we included systematic variations of the
consensus sequence for Abl (GEAIYAAPFA) [74,75], varying all
amino acids in each sequence position, one at a time. Finally, the
pool included the entire sequences of cortactin, Flt3, and Src,
proteins that each contain several known phosphorylation sites
[70], represented by overlapping 10-mer peptides with a step of
two amino acids.
We used Src (p60), Abl, Lck, Flt3, Kit, and Jak2 tyrosine kinases
in assays with the 3,243-plex peptide set. Preliminary analysis
revealed distinct patterns of phosphorylation for each of the
kinases tested (data not shown). In this report we present results for
Abl kinase (Fig. 5). Our pool included 1,690 peptides that
contained serine and threonine but no tyrosine residues (Group A,
Fig. 5), serving as a large collection of negative controls in the
experiments that measure only phosphorylation by tyrosine
kinases. Fig. 5 shows that the magnitudes of p-values for 1,690
negative peptides (group A) are clearly separated by orders of
magnitude from p-values of positive controls (group C), indicating
very high specificity and sensitivity of the assay. Group C (Fig. 5)
contained 198 peptides that were i) known to be substrates for Abl
kinase; or ii) systematic amino acid variants of a known Abl kinase
peptide substrate (GEAIYAAPFA). All known Abl kinase sub-
strates and the majority of the mutant peptides derived from the
GEAIYAAPFA wild type sequence were phosphorylated by Abl
kinase in our assay (a total 90% of Group C). More detailed results
for peptides derived from GEAIYAAPFA, in which amino acid
residues in the 23, 22, 21 +1, +2, and +3 positions flanking the
tyrosine phosphorylation site were systematically varied, are shown
in Fig. 6. The sequence preference observed for Abl kinase is
consistent with published data and known in vivo substrates
[74,75]. For example, we observed a strong requirement for
isoleucine at the 21 position and proline at the +3 position. Group
B contained 1,355 peptides that have at least one tyrosine residue
and therefore are potential substrates for Abl kinase. We found
that 53 peptides from Group B (4%) were phosphorylated by Abl
kinase. Of these, 38 peptides were previously reported as substrates
for Src, Lck, Flt3, and EphB2 kinases [69]. The 15 remaining
phosphorylated peptides included 6 peptides derived from
cortactin, Src, and Flt3 proteins: GTEPEPVYSM and GLAYA-
TEAVY (derived from the cortactin protein walk); SEEPIYIVTE
and LVQLYAVVSE (derived from the Src protein walk);
YATIGVCLLF and LSGPIYLIFE (derived from the Flt3 protein
walk); and 9 previously unassigned peptides.
Discussion
An intrinsically parallel way to convert an in silico specification
to a large collection of reagents is a technological cornerstone of
modern genomics approaches. For example, in applications such
as large-scale genotyping and targeted enrichment of genomic
regions, many oligonucleotides, made at low cost using parallel
Figure 3. HCV NS3/4A protease cleavage map of the 3,011 amino acid sequence of HCV polyprotein. Cleavage sites were identified by
assaying 3,001 overlapping 10-mer peptides covering the entire 3,011 amino acid sequence of HCV polyprotein. The graphs represent a response to
HCV NS3/4A protease treatment for three experiments (see Methods). The X-axis shows coordinates along the HCV polyprotein. The Y–axis represents
log-transformed p-values with sign showing directionality. Z-scores were transformed using -sign(z)x10xLog10(Pz) where Pz is p-value of derived
from standard normal distribution. Red dotted lines mark cutoffs computed from the maximum transformed Z-score in the negative direction.
Published HCV NS3/4A protease cleavage sites (1711, 1972, and 2420) are numbered in black. A new site (2172) is labeled in blue. The numbers in the
labels represent the position of the P1 amino acid (amino acid position at the C-terminus of the cleaved peptide bond) in the HCV polyprotein. Assay
signals that did not reach significance in all three experimental conditions (15, 30, and 60 minutes protease treatments from the top to the bottom
panels respectively), but were detected in at least two experimental conditions are labeled in red. The numbers in these labels represent the amino
acid position in the HCV polyprotein corresponding to the maximum of the peaks.
doi:10.1371/journal.pone.0037441.g003
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and assaying custom sets of thousands to millions of peptides is a
major technical barrier to proteome-scale analysis using peptide
libraries. Even a set of 1,000 peptides is quite large by the
standards of conventional technologies. Although such collections
can be made, they are expensive, and they would not necessarily
be usable for parallel, low-cost analysis. In this work we adapted
and integrated existing genomics technologies to develop a new
technology for proteomics. In our approach, large collections of
custom peptide sequences, designed in silico, are made as peptide-
cDNA conjugates and then used in highly multiplexed assays.
Our rationale for making the peptides as conjugates with their
encoding DNA sequences was to enable the readout of results by
digital nucleic acid sequencing. Together with the development of
intrinsically parallel ways to assay pools of peptides, this ensures
that our entire process is highly scalable and cost-efficient. Given
that not all substrates in a large pool are cleaved, or phosphor-
ylated, and therefore do not generate signal, the capacity of the
current generation of massively parallel DNA sequencers is
already sufficient to screen peptide sets of $1 million at a low
cost per data point. As a readout technology, digital sequencing is
flexible, with the ability to adjust sensitivity and dynamic range by
the number of reads obtained. Our method is also quite specific. It
benefits from the single nucleotide discrimination provided by
DNA sequencing, which allows us to filter out the small fraction of
data points that may have been produced by incorrectly encoded
peptides. At the peptide level, the ability to tile through a protein
sequence with overlapping peptides provides redundancy, which
also improves sensitivity and specificity. Multiple peptides span-
ning a protein site of interest can each generate a signal, as shown
in Figs. 4 and 6, which helps with positive signal identification
during data analysis.
We showed that our peptide sets are functional in protease
assays by screening the entire HCV polyprotein and identifying a
small number of ‘hits’ for subsequent confirmation. Our approach
enabled de novo identification of all three known trans-cleavage sites
of the HCV NS3/4A protease in the 3,011 amino acid long HCV
polyprotein, recapitulating results from the literature [56]. We also
confirmed two new sites (
2168VAVLTQSMLTD
2177 and
672QVLPCQSFTTL
681). Similarly, we demonstrated the feasibil-
ity of discovering kinase substrates by screening the potential
phosphoproteome, using peptides designed from genomic se-
Figure 4. Results from peptides spanning the cleavage sites 1711, 1972, 2172, and 2420. The plots show data from sets of overlapping
10-mer peptides representing portions of the HCV polyprotein where protease activity was detected at all three time points in our assay (Fig. 3). Red
dotted lines mark cutoffs computed from the maximum transformed Z-score in the negative direction. The Y–axis represents log-transformed p-
values with the sign showing directionality. Z-scores were transformed using -sign(z)x10xLog10(Pz) where Pz is the p-value derived from standard
normal distribution. Because the peptide sequences are shifted in increments of 1 amino acid, several adjacent peptides contain sufficient
recognition sequences to be cleaved. Peptide sequences are written vertically and the HCV NS3/4A protease recognition sequences corresponding to
identified P4-P4’ positions are shown in red.
doi:10.1371/journal.pone.0037441.g004
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consensus sequence mutational analysis (Fig. 6) and Abl reactivity
on known substrates of other tyrosine kinases, provided a
characterization of substrate preferences. These results show that
one possible application of our technology is to identify sets of
substrates that can be used as specificity ‘fingerprints’ to maximize
the power to distinguish the activity of different kinases or
proteases with similar specificities.
Figure 5. Abl kinase phosphorylation map of a 3,243-plex peptide substrate pool. Each bar along the X-axis corresponds to a signal from
an individual peptide in the pool. In order to simplify visualization, peptides were split into three groups. Group A contains 1,690 peptides that do not
have any tyrosine residues and includes 19 negative control peptides that are derived from a known Abl kinase peptide substrate (GEAIYAAPFA)
where the tyrosine residue was changed to all remaining 19 natural amino acids while the rest of the sequence was kept constant. Group B contains
1,355 peptides that have at least one tyrosine residue. Group C contains 198 peptides that are known to be substrates for Abl kinase or derived from
a known Abl kinase peptide substrate (GEAIYAAPFA) where amino acid residues in each individual position (except the tyrosine residue) were
systematically changed to all remaining 19 natural amino acids while the rest of the sequence was kept constant. The Y–axis represents log-
transformed p-values with sign showing directionality. Red dotted lines mark cutoffs corresponding to the maximum Z-score observed for peptides
lacking tyrosine. Z-scores were transformed using -sign(z)x10xLog10(Pz) where Pz is the p-value derived from standard normal distribution.
doi:10.1371/journal.pone.0037441.g005
Figure 6. Sensitivity of Abl kinase to sequence variation as a function of position. Each panel shows the effect of varying the amino acid
sequence at one position in the Abl kinase substrate GEAIYAAPFA. The position that is varied (top left of each panel) is shown relative to the central
tyrosine, which is in the ‘0’ position. The amino acid that is substituted at the position of interest is shown on the X-axis, with the reference sequence
shown in red. The Y–axis represents log-transformed p-values with sign showing directionality. The data are a subset of the 3,243-plex pool data
shown in Fig. 5 (Group C).
doi:10.1371/journal.pone.0037441.g006
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(
2168VAVLTQSMLTD
2177 and
672QVLPCQSFTTL
681) identi-
fied in our assay are located in the central region of NS5A RNA
polymerase and in the E2 protein respectively and may not be
readily accessible for proteolysis under physiological conditions in
vivo. Therefore, these sites are unlikely to be biologically relevant.
However, our results also illustrate the ability to identify in vivo
relevant and functionally significant sites. Our kinase assay, as well
as several in vivo global studies using mass spectrometry, have
identified GTEPEPVYSM as a phosphorylation site in cortractin
[76,77]. This phosphorylated tyrosine is one of the key regulatory
points of cortactin in response to stress [78]. These two examples
from the opposite sides of spectrum illustrate one limitation of our
approach. Because we represent a protein sequence in the form of
multiple short peptides and carry out assays in vitro, there may be
significant conformational and accessibility differences that limit
the ability to extrapolate results to the protein and in vivo context.
Therefore, additional filtering may be required to distinguish sites
that are functional in vivo from those that are active only in vitro on
the peptide level. For example, one approach may be to make use
of 3-dimensional protein structural information to compute
theoretical accessibility of individual peptides mapped on the
structure.
Another limitation is that our peptides are produced without
post-translation modifications, and therefore in some cases may
not reflect the situation in vivo, where proteins undergo a wide
variety of modifications, such as acetylation, phosphorylation,
glycosylation, or disulfide bridge formation [79,80]; although our
production protocol could be modified to make peptide-cDNA
libraries with modified or unnatural amino acids [81–83].
Additionally, a possible source of biases may be interference of
cDNA tags with enzymatic activity on peptides leading to false-
negatives. However, we have not observed this to be a problem
since signals from all positive controls in both assays were detected.
Nevertheless, the sheer breadth of sequences that we are now able
to assay should make this technology a useful discovery tool. The
ability to survey large tracts of sequences, as well as systematic
variations that can be designed in silico, enables comprehensive
analysis of sequence dependences, and can provide insights into
function (see accompanying paper [65]).
Despite these limitations, the ability to screen large amounts of
sequences rapidly and efficiently enables the discovery of new
protease and kinase targets. Importantly, because of the parallel
design of our approach, even orders of magnitude increase in the
number of peptide–cDNA conjugates that are made and assayed
would have a relatively modest impact on cost. Prior to our
technology, approaches for the identification of protease and
kinase substrates have been developed that employ individually
synthesized peptide substrates [84–89]. The high cost of synthe-
sizing peptides individually limits these approaches for large-scale
screening of sequences. The cost of peptides produced by parallel
synthesis is much lower [90–92] but the current price of peptide
microarrays is still a barrier to large scale studies [93]. Recently, a
method for the production of low cost oligonucleotide libraries has
been developed in parallel with our approach [94] and used to
generate a phage displayed peptide library with 413,000 members
[46]. This library was successfully used to identify autoantigens,
and also served to illustrate the power of parallel approaches. In
principle, phage libraries could also be used for protein activity
assays, and our peptide-cDNA conjugate libraries for binding
assays. However, peptide-cDNA conjugates are much lower in
molecular weight, which reduces the opportunity for non-specific
interactions, and may make it more straightforward to adapt to
different types of assays. Also, our process can be carried out
completely in vitro, which may help to avoid cloning and
propagation biases that may occur with phage libraries.
The approach presented in this report should scale to sets that
are orders of magnitude larger. In order to realize the full potential
of our approach, we plan to scale up the level of multiplexing and
also develop additional assays, such as assays for serine and
threonine kinases. In conclusion, we believe that our technology
has the potential to open up new opportunities for designing and
using large custom peptide sets. We expect that it will stimulate the
development and application of a variety of proteome-wide assays
for basic and applied research.
Methods
DNA Pool Production
DNA pools were synthesized via a microarray based method
that is similar to a previously published approach [46]. Briefly,
single-stranded oligonucleotide templates (ssDNAs) encoding the
peptide sequences were synthesized on the array surface and
phosphorylated using T4 polynucleotide kinase. Each of the
templates has a universal 5-mer site at the 5’-end for splint ligation
and a universal primer site at the 3’-end coding for a common tag.
A universal DNA sequence was ligated to all oligonucleotides on
the array using T4 DNA ligase and a splint oligonucleotide. This
sequence contains an untranslated region (UTR) with a T7
promoter and a ribosomal binding site (RBS). Next, a universal
primer was hybridized to the 3’-end of all sequences on the array.
The primer was extended by DNA polymerase and the resulting
ssDNAs were eluted from the array and amplified by PCR.
Synthesis of Puromycin DNA Adaptor
The DNA adaptor consists of a DNA oligonucleotide with a 5’
phosphate modification and a 3’ puromycin residue attached via a
polyethylene glycol (PEG) linker [95], and a DNA oligonucleotide
with a 5’ psoralen residue, complementary to the puromycin
modified oligonucleotide and the 3’ end of RNAs. The two
oligonucleotides were annealed and covalently linked by psoralen-
induced photo-crosslinking [8,96].
Synthesis of RNA-puromycin Molecules
Amplified DNA pools were transcribed using a standard
protocol (AmpliScribe T7 Flash, EpiCentre). Transcription
reactions were cleaned up using Qiagen RNeasy Mini Kit and
quantified. The DNA adaptor was attached to the 3’ end of RNAs
via template directed ligation [8]. Ligated RNA molecules were
purified using 15% TBE-Urea denaturing gel.
Generation of cDNA Peptide Fusions
The RNA-puromycin molecules were translated in vitro, and
then converted into cDNA following published protocols [8]. The
peptide-cDNA pools were treated with RNAse H and RNAse A,
and then captured via complementary oligonucleotides attached to
silica beads. All peptide-cDNA conjugates contained a modified
TEV protease cleavage sequence (GENLYFQCA) at the N-
terminus. Treatment with AcTEV protease (Invitrogen) exposed
an N-terminal cysteine residue [97] that was then modified with
biotin-PEG in the form of a thioester [98]. Next, the biotinylated
products were eluted from the beads for use in either the protease
or kinase assay as described below. A portion of the pool was set
aside for sequencing to characterize peptide representation in the
starting peptide-cDNA pool. In order to confirm that all peptide-
cDNA conjugates were present in the multiplexed pools, the pools
were immobilized on streptavidin beads via biotin attached to the
peptide portion of the conjugates (Fig. 1, step iv). After washing
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the immobilized conjugates were eluted with 95% formamide for
10 min at 95uC, PCR amplified, and sequenced.
Protease Assay
Solution containing peptide-cDNA conjugates (10 mLo f
,0.1 mM in water) was diluted two-fold with Superblock (Thermo
Scientific). A magnetic streptavidin bead suspension (2 mLo f1 %
solids, Seradyn) was added and the mixture was incubated for 15
minutes at room temperature. The beads were washed three times
with 100 mL1 6 PBS 0.05% Tween 20 to remove unbound
conjugates. Next, the beads were suspended in 10 mL of protease
solution with HCV NS3/4A protease (Anaspec) at 20 mg/mL in
50 mM Tris HCl pH 7.5 buffer containing 100 mM NaCl,
10 mM DTT, 20% glycerol. The immobilized conjugates were
exposed to the solution at 37uC with samples being collected at 15,
30, and 60 minutes. Negative controls were subjected to identical
conditions without protease present. Samples were taken from the
supernatant, filtered to remove any leftover beads, and prepared
for sequencing as described below.
Kinase Assay
The peptide-cDNA conjugates (,0.1 mM) were treated with 20
units of Abl kinase (New England Biolabs) in 50 mM Tris-HCl
pH 7.5 buffer containing 10 mM MgCl2, 2 mM DTT, 0.1 mM
EDTA, 0.01% Brij-35, and 750 mM ATP. Untreated sample was
used as a negative control and was processed in parallel in the
absence of kinase. Reactions were carried out at 32uC for 1 hour.
After phosphorylation, peptide-cDNA conjugates were captured
on streptavidin beads, followed by elution in water at 95uC.
Phosphorylated peptide-cDNA molecules were captured from
each sample using magnetic beads with immobilized anti-
phosphotyrosine antibodies [40,54] (Millipore). Enriched phos-
phorylated peptides were eluted with 1 mM phenyl phosphate
solution in PBS with 0.05% Tween 20 and prepared for
sequencing as described below.
Library Preparation and Sequencing
DNA libraries produced by the protease or kinase assay were
amplified, and sequencing adapters incorporated, by PCR [99].
Typically, 25 cycles of PCR were needed to produce sufficient
amounts of material for sequencing. When appropriate, unique
barcodes were incorporated during PCR and multiple libraries
were pooled prior to purification. PCR products were then
purified by PAGE on 6% polyacrylamide TBE gels (Invitrogen),
eluted in 0.1X TE buffer and precipitated with ethanol in the
presence of 100 mM sodium acetate and 1 mL of Pellet Paint
(EMD Chemicals). The PCR product was dissolved in water and
sequenced using a Genome Analyzer IIx following a standard
protocol (Illumina).
Protease Assay Data Analysis
Prior to statistical analysis, products made from DNA templates
with spontaneous mutations (arising from errors in DNA synthesis
or nucleic acid amplification) were identified by sequencing data
analysis and filtered out in silico. Three pairs of protease treated
and untreated samples (15, 30, and 60 minutes) were compared in
each experiment (see Raw Assay Data S1). In order to reduce the
impact of noise at low signal levels, raw sequence counts were log2
transformed after adding 256 virtual counts. A smoothing spline
was then fitted using the smooth.spline routine from the R
statistical package. The residuals from the fit were converted to Z-
scores after scaling by a standard deviation estimated via median
absolute deviation. Z-scores were further smoothed along the
HCV polyprotein sequence by a 3 amino acid moving median
filter. Under a no cleavage hypothesis the distribution of resulting
Z-scores is expected to be symmetric. Therefore, we used the
absolute value of the maximum negative Z-score as a cutoff to call
cleavage events in each pair of samples.
Kinase Assay Data Analysis
Prior to statistical analysis, products made from DNA templates
with mutations were filtered out in silico as described above for
protease assay. Four Abl kinase treated and untreated pairs of
samples were compared (see Raw Assay Data S2). Raw sequence
counts were log2 transformed after adding 512 virtual counts to
reduce the impact of noise. A smoothing spline was fitted with
df=4 argument to the smooth.spline routine and zero weight was
given to points corresponding to known Abl substrates. The
residuals were converted to Z-scores the same way described
above for the protease assay. We used the maximum Z-score of
peptides containing no tyrosine as a cutoff for rejecting no
phosphorylation hypothesis.
Supporting Information
Text S1 Confirmation of Putative NS3/4A Protease
Substrates. Experimental design, methods, and results of
cleavage analysis performed on chemically synthesized peptides
treated with NS3/4A protease.
(DOCX)
Table S1 Results for Confirmation of Putative NS3/4A
Protease Substrates. A plus sign (+) indicates that cleavage by
HCV NS3/4A protease was observed. A minus sign (2) indicates
that cleavage was not observed. N/A indicates a sample that was
not analyzed. The column ‘‘Cleavage Site’’ shows positions of the
cleavage sites identified by LCMS assay (designated with arrows).
The ‘‘Peptide Assay’’ column summarizes results of our assay
shown in Fig. 3.
(DOCX)
Raw Assay Data S1 Protease Assay Raw Data (HCV
NS3/4A protease). Sequencing counts for each peptide and
specific treatment condition are presented. Three pairs of protease
treated and untreated samples (15, 30, and 60 minutes) were
compared in each experiment (15, 30, and 60 HCV plus/minus,
respectively).
(CSV)
Raw Assay Data S2 Kinase Assay Raw Data (Abl kinase).
Sequencing counts for each peptide and specific treatment
condition are presented. Four Abl kinase treated and untreated
pairs of samples were compared (Abl plus/minus 1–4).
(CSV)
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